Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Aquinox, Astellas Mull Options As Rosiptor Fails

Jun 29 2018

• By Ian Haydock

Empty dirt road which splits in two, concept for life choices or decisions — ROSIPTOR FAILURE PROMPTS AQUINOX STRATEGIC REVIEW • Source: Shutterstock

Related Content

US FDA Weighs Whether Interstitial Cystitis Should Be Studied Separately From Bladder Pain

Dec 05 2017

Deal Watch: Novo’s Increased Cell Therapy Commitment Includes Stem Cell Pact With BioLamina

May 16 2018

Astellas Culls Positions Ahead Of Big Expiry

May 25 2018

Related Companies

Astellas Pharma, Inc.

Neoleukin Therapeutics, Inc.

Johnson & Johnson

Viatris Inc.

Urigen Pharmaceuticals, Inc.

Harrow, Inc.

Additional Topics

Japan Asia Pacific United States Commercial Business Strategies Clinical Trials Inflammation BioPharmaceutical

More from Business

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window